Related Experiment Videos
Intermittent dosing of alendronate
1School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis, IN, USA.
The Annals of Pharmacotherapy
|November 29, 2001
Summary
Intermittent alendronate dosing may improve patient compliance and reduce adverse events, but more research is needed. The effectiveness of this dosing schedule for postmenopausal osteoporosis is still undetermined.
Area of Science:
- Pharmacology
- Clinical Medicine
- Osteoporosis Research
Background:
- Alendronate is a bisphosphonate commonly used for osteoporosis.
- Traditional daily dosing can be associated with compliance issues and gastrointestinal side effects.
Purpose of the Study:
- To review existing data on the use of intermittent dosing of alendronate.
- To assess the potential benefits of intermittent dosing for patient compliance and adverse event profiles.
Main Methods:
- A comprehensive literature search was performed.
- Databases searched included MEDLINE and EMBASE.
- The search focused on studies evaluating intermittent alendronate dosing.
Main Results:
- A limited number of clinical studies have investigated intermittent alendronate dosing.
- These studies aimed to improve patient adherence and mitigate adverse events.
Conclusions:
- Further controlled clinical trials and postmarketing data are required.
- The therapeutic efficacy and tolerability of intermittent alendronate dosing need to be confirmed.
- The definitive role of intermittent dosing in managing postmenopausal osteoporosis remains uncertain.